Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma (Alternative)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02689869
Recruitment Status : Active, not recruiting
First Posted : February 24, 2016
Last Update Posted : September 4, 2019
Sponsor:
Collaborators:
Hoffmann-La Roche
Janssen-Cilag G.m.b.H
Information provided by (Responsible Party):
Prof. Dr. Wolfgang Hiddemann, Ludwig-Maximilians - University of Munich

Tracking Information
First Submitted Date  ICMJE February 4, 2016
First Posted Date  ICMJE February 24, 2016
Last Update Posted Date September 4, 2019
Study Start Date  ICMJE April 2016
Estimated Primary Completion Date April 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 18, 2016)
Progression free survival [ Time Frame: one year progress free survival ]
The rate of patients archiving a progression free survival of more than one year after registration (one-year PFS) will serve as early readout for efficacy and will be the primary endpoint of this trial.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02689869 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 18, 2016)
  • three-year-PFS [ Time Frame: three years after start of therapy ]
    Progression free survival after start of therapy (continuous observation)
    • three-year-PFS
  • CR [ Time Frame: one year after start of therapy and at 30 months after end of maintenance ]
    CR rates at end of induction CR rates one year after start of therapy CR rates after end of maintenance therapy (at 30 months after start of therapy: CR30)
  • PR [ Time Frame: one year after start of therapy and at 30 months after end of maintenance ]
    PR rates at end of induction PR rates one year after start of therapy PR rates after end of maintenance therapy (at 30 months after start of therapy: CR30)
  • SD [ Time Frame: one year after start of therapy and at 30 months after end of maintenance ]
    SD rates at end of induction
  • Duration of response [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Duration of Response
  • Percentage of Progression [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Percentage of progression during induction and maintenance therapy
  • TTF after start of therapy [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Time to treatment failure after start of therapy (failure defined by failure to achieve a CR/PR after 6 months or progression after CR or PR or death in remission)
  • Time to next anti-lymphoma therapy / time to next chemotherapy based treatment [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Time to next anti-lymphoma therapy and time to next chemotherapy based treatment
  • Treatment associated adverse events [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Treatment associated adverse events
  • Percentage of MRD negative patients during therapy [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Percentage of MRD negative patients during induction therapy (midterm), after induction therapy and after maintenance therapy
  • Duration of molecular remission [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Duration of molecular remission for MRD negative patients after the end of induction and maintenance
  • Percentage of secondary transformation [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Percentage of secondary Transformation to aggressive lymphoma
  • Percentage of secondary malignancies [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Percentage of secondary malignancies
  • Time to first secondary malignancy [ Time Frame: 4,5 up to 6,5 years through study completion ]
    Time to first secondary malignancy
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
Official Title  ICMJE A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden
Brief Summary

Primary Objectives The primary objective of this study is to evaluate the efficacy of the chemotherapy-free combination of ibrutinib and obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma (FL) and a high tumor burden. Primary endpoint to be observed for this is the rate of progression free survival one year after start of therapy.

Hypothesis The hypothesis of the study is that ibrutinib in combination with obinutuzumab will achieve response rates (CR and PR), rates of MRD negativity and PFS which are comparable to currently used standard rituximab-chemotherapy combinations such as R-CHOP or R-bendamustine in subjects with previously untreated FL and a high tumor burden.

Detailed Description

OVERVIEW OF STUDY DESIGN This is a prospective, multicenter phase 2 study in up to 98 subjects with previously untreated FL and a high tumor burden in advanced stages and in need of therapy. The study will include a central monitoring of MRD by PCR, a central pathologic review and complimentary research projects including monitoring of immune response.

The study therapy comprises an initial 6 cycles of ibrutinib plus obinutuzumab followed by an additional 24 months of ibrutinib plus obinutuzumab maintenance.

In patients being MRD negative at 30 months, i.e. at the end of ibrutinib plus obinutuzumab maintenance, and without clinical progression no further treatment is given while MRD monitoring is continued.

MRD monitoring will be regularly performed on peripheral blood samples collected before the start of therapy and at months 3, 6, 9, 12, 18, 24 and 30 respectively. Subsequently, MRD analyses will be performed every 6 months until clinical progression of the disease or for a maximum of 4 years (until the end of the study).

If MRD assessment on peripheral blood samples turns from positive to negative within the first 30 months, confirmatory blood and bone marrow samples should be taken 6 months thereafter.

In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months.

An independent Data Monitoring Committee (DMC) will be formed and constituted. The independent DMC will review the safety of the treatment and make recommendations as to the further conduct of the study.

The data generated by this phase II study should serve as the basis for a subsequent randomized phase III study comparing the chemotherapy-free combination of ibrutinib plus obinutuzumab with standard immune-chemotherapy.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Indolent Non-Hodgkin Lymphoma
Intervention  ICMJE
  • Drug: Ibrutinib
    Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
    Other Name: Imbruvica
  • Drug: GA 101
    Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
    Other Name: Obinutuzumab
Study Arms  ICMJE Experimental: Ibrutinib and GA 101

Initial therapy 6 cycles of Ibrutinib:

Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.

1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).

Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:

Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.

In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months.

Interventions:
  • Drug: Ibrutinib
  • Drug: GA 101
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: February 18, 2016)
98
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2022
Estimated Primary Completion Date April 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Histologically confirmed follicular lymphoma grade 1, 2 or 3A with a lymph node biopsy performed within 12 months before study entry and with material available for central review and complementary scientific analyses

  • Ann Arbor stage III/IV, or stage II not suitable for radiotherapy, or stage II bulky disease
  • Age ≥ 18 years
  • No prior lymphoma therapy
  • Need for start of therapy as defined by:

    • bulky disease at study entry according to the GELF criteria (nodal or extranodal mass >7 cm in its greater diameter)
    • and/or B symptoms (fever, drenching night sweats, or unintentional weight loss of >10% of normal body weight over a period of 6 months or less)
    • and/or hematopoietic insufficiency (granulocytopenia < 1.500/µl, Hb < 10 g/dl, thrombocytopenia < 100.000/µl)
    • compressive syndrome or high risk for compression syndrome
    • and/or pleural/peritoneal effusion
    • and/or symptomatic extranodal manifestations
  • At least one bi-dimensionally measurable lesion (> 2 cm in its largest dimension by CT scan or MRI)
  • Performance status ≤ 2 on the ECOG scale
  • Adequate hematologic function (unless abnormalities are related to NHL), defined as follows:

    • Hemoglobin ≥ 9.0 g/dL
    • Absolute neutrophil count ≥ 1500 /µl
    • Platelet count ≥ 75000 /µl
  • Women are not breast feeding, are using highly effective contraception, are not pregnant, and agree not to become pregnant during participation in the trial and during the 18 months thereafter (pregnancy testing is mandatory for premenopausal women).
  • Men agree not to father a child during participation in the trial and during the 18 months thereafter.
  • Written informed consent

Exclusion Criteria:

  • - Transformation to high-grade lymphoma (secondary to "low grade" FL)
  • Grade 3B follicular lymphoma
  • Presence or history of CNS disease (either CNS lymphoma or leptomeningeal lymphoma).
  • Known hypersensitivity to any of the study drugs
  • Known sensitivity to murine products
  • Regular use of corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisone.
  • Concomitant use of strong CYP3A4 inhibitors and / or oral anticoagulants (warfarin and/or phenprocoumon)
  • Prior or concomitant malignancies except:

    • non-melanoma skin cancer or adequately treated in carcinoma in situ of the cervix
    • Other malignant diseases not specified above which have been curatively treated by surgery alone and from which subject is disease-free for ≥5 years without further treatment
  • Serious disease interfering with a regular therapy according to the study protocol:

    • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
    • pulmonary (e.g. chronic lung disease with hypoxemia)
    • endocrine (e.g. severe, not sufficiently controlled diabetes mellitus)
    • renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinine clearance < 50 ml/min)
    • impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl (unless caused by known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
  • Positive test results for chronic HBV infection (defined as positive HBsAg serology) Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination or prior but cured hepatitis B are eligible.
  • Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
  • Known history of HIV seropositive status.
  • Patients with a history of confirmed PML
  • Vaccination with a live vaccine within 28 days prior to registration
  • Recent major surgery (within 4 weeks prior to the start of Cycle 1)
  • History of stroke or intracranial hemorrhage within 6 months prior to registration
  • Serious underlying medical conditions, which could impair the ability of the patient to undergo the treatment offered in the study (e.g. ongoing infection, gastric ulcers, active autoimmune disease)
  • Treatment within a clinical trial within 30 days prior to trial entry.
  • Prior organ, bone marrow or peripheral blood stem cell transplantation
  • Known or persistent abuse of medication, drugs or alcohol
  • Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02689869
Other Study ID Numbers  ICMJE 2014-005164-15
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Prof. Dr. Wolfgang Hiddemann, Ludwig-Maximilians - University of Munich
Study Sponsor  ICMJE Ludwig-Maximilians - University of Munich
Collaborators  ICMJE
  • Hoffmann-La Roche
  • Janssen-Cilag G.m.b.H
Investigators  ICMJE
Principal Investigator: Wolfgang Hiddemann, Prof. Klinikum der Universität München
PRS Account Ludwig-Maximilians - University of Munich
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP